Enrollment is complete in a phase 2 clinical trial of AR-1105 for the treatment of macular edema associated with retinal vein occlusion, Aerie Pharmaceuticals announced in a press release.
The trial, which is taking place at 19 U.S. centers, is evaluating the safety, tolerability and efficacy of AR-1105 (dexamethasone intravitreal implant).
“We are grateful to our investigators and the patients who have enrolled in this proof-of-concept study for our proprietary sustained-release technology,” Vicente Anido Jr., PhD, Aerie chairman and CEO, said in the release. “We plan to
Uncategorized